Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions

Social Science and Medicine

Volumn 45, Issue 4, 1997, Pages 535-544

  Grabowski, Henry ^a   Mullins, C Daniel ^b  

^a DUKE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC DISEASE; COOPERATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE MANAGEMENT; DRUG COST; DRUG FORMULARY; DRUG MANUFACTURE; GOVERNMENT; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; METHODOLOGY; PHARMACOECONOMICS; PHARMACY;

COST CONTROL; DRUGS, GENERIC; FORECASTING; FORMULARIES, HOSPITAL; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MANAGED CARE PROGRAMS; PRACTICE GUIDELINES; UNITED STATES;

EID: 0030745126     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0277-9536(96)00394-2     Document Type: Article

References (23)

1. Barradell, L. B., Whittington, R. and Benfield, P. (1993) Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by non-steroidal anti-inflammatory drugs. PharmacoEconomics 3(2), 140-173.
2. Blissenbach, H. F. (1993) Pharmaceutical services in managed care. In The Managed Health Care Handbook, 2nd edn, ed. P. Kongfvedt, pp. 142-160. Aspen, Gaithersburg, MD.
3. Coyle, D. and Drummond, M. (1993) Does expenditure on pharmaceuticals give good value for money: current evidence and policy implications. Health Policy 26, 55-75.
4. U.S. Food and Drug Administration (FDA) Principles for the review of pharmacoeconomic promotion. Draft manuscript, FDA.
5. Gifford, R. W.et al. (1993) The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Archives of Internal Medicine 153, 154-181.
6. Goldman, L., Weinstein, M. C., Goodman, P. A. and Williams, L. W. (1991) Cost-effectiveness of HMG-CoA reductase inhibitors for primary and secondary prevention of coronary heart disease. Journal of the American Medical Association 265(9), 1145-1151.
7. Grabowski, H. G. (1988) Medicaid patients' access to new drugs. Health Affairs Winter, 102-114.
8. Grabowski, H. G. (1995) Price and profit control, new competitive dynamics and the economics of innovation in the pharmaceutical industry. In Industrial Policy and the Pharmaceutical Industry, ed. A. Towse, pp. 77-91. Office of Health Economics, London.
9. Grabowski, H. G. and Vernon, J. M. (1992) Brand loyalty entry and price competition in pharmaceuticals after the 1984 act. Journal of Law and Economics 35, 331-350.
10. Grabowski, H. G. and Vernon, J. M. (1994) Returns to R&D on new drug introductions in the 1980s. Journal of Health Economics 13, 383-406.
11. Grabowski, H. G. and Vernon, J. M. (1996) Longer patents for increased generic competition: the Waxman-Hatch Act after one decade. PharmacoEconomics 10(2), 110-123.
12. Hay, J. W., Wittels, E. H. and Grotto, A. M. (1991) An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. American Journal of Cardiology 67(9), 789-796.
13. Health Strategies Group (1995) Pharmacy Benefit Management. HSG, Palo Alto, CA.
14. Martens, L. L., Rutten, F. F. H., Erkelens, D. W. and Ascoop, C. A. P. L. (1989) Cost-effectiveness of cholesterol-lowering therapy in the Netherlands: simvostatin versus cholestramine. American Journal of Medicine 87(4A), 545-585.
15. Moore, W. J. and Newman, R. J. (1992) U.S. Medicaid drug formularies: do they work. PharmacoEconomics 1(1), 28-31.
16. National Cholesterol Education Program (1988) Report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Archives of Internal Medicine 148, 36-69.
17. National Cholesterol Education Program (1994) Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Circulation 89(3), 1333-1445.
18. Oster, G., Borok, G. M., Menzin, J., Heyse, J. F., Epstein, R. S., Quinn, V., Benson, V., Diedl, R. J. and Epstein, A. M. (1996) Cholesterol-Reduction Intervention Study (CRIS): randomized trial to assess effectiveness and costs in clinical practice. Archives of Internal Medicine.
19. Schulman, K. A., Kinosian, B., Jacobson, T. A., Glick, H., Willian, M. K., Koffer, H. and Eisenberg, J. M. (1990) Reducing high blood cholesterol with drugs. Journal of the American Medical Association 264(23), 3025-3033.
20. Shaw, H. K. (1992) Catalysts for Change: The Impact of Generic Drugs on the Pharmaceutical Industry Spectrum. Report 38-8, Decision Resources, Burlington, MA.
21. Treppell, J. (1994) Generic Industry Drug Interview. Kidder Peabody, New York.
22. U.S. Department of Health and Human Services (1991) Guidelines for the Diagnosis and Management of Asthma. National Asthma Education Program Expert Panel Report, NIH No. 91-3042, Bethesda, MD.
23. U.S. General Accounting Office (1995) Early Results on Ventures with Drug Manufacturers. GAO/HEHS-96-45, General Accounting Office.